At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved — [verify projected brand name] |
| Targets | GLP-1R + AMYR/CTR (GLP-1 + amylin co-agonism) |
| Developer | Novo Nordisk |
| Modality | SC injection, once-weekly (co-formulated single pen) |
| Approval status | Phase 3 — REDEFINE 1 data reported; filing [verify] |
| Key efficacy | ~22.7% weight loss at 68 weeks (REDEFINE 1, Phase 3) |
| Indications | Obesity, T2D |
User Sentiment
CagriSema trial participants describe the appetite suppression as more complete than semaglutide alone — consistent with two separate satiety circuits being activated. The most common theme is reduced interest in food at a more fundamental level than people experienced on semaglutide alone.
Example(What REDEFINE participants report)
Phase 3 REDEFINE 1 participants noting the difference from previous semaglutide experience describe it as "an extra layer of not wanting to eat" — the GLP-1 component handled the meal-size reduction they already knew, and the amylin component added something to the between-meal cravings that semaglutide alone hadn't addressed as fully.
How it works
A co-formulated weekly injection containing semaglutide (GLP-1R agonist) and cagrilintide (an amylin analog activating AMYR/CTR). Two separate molecules, one injection, two distinct receptor pathways.
Amylin is a pancreatic hormone co-secreted with insulin after meals. It signals satiety through the area postrema and nucleus tractus solitarius in the brainstem — anatomically distinct from GLP-1's hypothalamic satiety pathway. The combination theory: two different satiety circuits, additive effect, no receptor redundancy.
The phase 2 data initially disappointed — 15.6% at 32 weeks was comparable to semaglutide alone. Phase 3 at longer duration and higher doses showed the combination advantage clearly: ~22.7% at 68 weeks.
Intuition(Two satiety circuits, not one)
GLP-1 acts primarily on the hypothalamus — the brain's energy balance center. Amylin acts on the area postrema and nucleus tractus solitarius in the brainstem — a different anatomical region with different input signals. Hitting both circuits simultaneously is the mechanistic bet behind CagriSema: two parallel pathways to reduced food intake that don't compete for the same receptor or signaling cascade. The Phase 3 data at longer duration suggests the combination advantage compounds over time in a way that hitting one circuit alone doesn't.
Trial data
Phase 2 COMBINE 1 (32 weeks): 15.6% weight loss — comparable to semaglutide alone at this timeframe.
REDEFINE 1 (Phase 3, obesity, 68 weeks): ~22.7% weight loss — substantially outperforming semaglutide and competitive with tirzepatide's SURMOUNT-1. The longer duration is where the amylin combination advantage became visible.
REDEFINE 2 (T2D), REDEFINE 3 (CVD outcomes): [verify current status].
Intuition(Why the combination advantage shows at longer duration)
The brainstem amylin pathway and the hypothalamic GLP-1 pathway may have different time dynamics in their adaptation to sustained drug exposure. The incremental benefit of hitting two satiety circuits appears to compound over longer treatment — which is why Phase 2 at 32 weeks looked like semaglutide and Phase 3 at 68 weeks looked like something substantially better.
What to Expect
Weeks 1–4 — Nausea more pronounced than semaglutide alone — two appetite-suppressing mechanisms mean two gastric-slowing mechanisms. Slow titration is important here.
Month 2–3 — The two-circuit appetite suppression becomes apparent. People who were already on semaglutide describe it as stepping up a level.
Month 6 — Based on REDEFINE 1: ~22.7% at 68 weeks puts the 6-month marker around 15–18% for most participants.
Month 12–18 — The full 22.7% average lands here. The combination advantage is a long-duration effect.
Dosing and administration
Once-weekly subcutaneous injection from a co-formulated pen. Slow titration similar to Wegovy — starting at lower doses and escalating over 16–20 weeks to 2.4mg semaglutide + 2.4mg cagrilintide maintenance [verify final titration schedule against approved label].
Development status
| Milestone | Status |
|---|---|
| Phase 2 COMBINE 1 | Complete — 15.6% at 32 weeks |
| REDEFINE 1 (obesity) | Complete — 22.7% at 68 weeks |
| REDEFINE 2 (T2D) | [verify current status] |
| REDEFINE 3 (CVD) | [verify current status] |
| FDA filing | [verify — expected 2025–2026] |
Safety profile
GI side effects additive from both components — nausea and vomiting rates higher than semaglutide alone, consistent with two complementary gastric-slowing mechanisms. Discontinuation rates due to GI adverse events [verify vs semaglutide comparator in REDEFINE 1]. Same thyroid C-cell black box warning via semaglutide component. No novel safety signals attributable to cagrilintide identified in Phase 3 data to date.
Who It's For
- Adults with obesity (BMI ≥ 30 or ≥ 27 with weight-related conditions)
- People who've been on semaglutide and want the next step up before tirzepatide or retatrutide
- T2D patients — REDEFINE 2 is developing the diabetes indication
Not yet approved — filing timeline pending REDEFINE 2/3 completion. Watch for Novo Nordisk's submission announcement.
Summary(The CagriSema picture)
Phase 2 disappointed (15.6% at 32 weeks — comparable to semaglutide alone). Phase 3 delivered (22.7% at 68 weeks — substantially better). The duration dependence is the key scientific finding: the amylin combination advantage isn't visible at 32 weeks but is real at 68. Nearest to approval in the emerging modalities family.